The Florida biotechnology segment is creating new opportunities for local employment seekers, which is displayed in recent statistics. According to the South Florida Sun Sentinel, data showed that venture capitalists invested $103.5 million in this sector in 2012 – a 19 percent year-over-year increase.
New investments provide biotechnology firms with additional resources in a number of areas, including their work teams. The news source notes that the Sunshine State's life science segment is expanding at a faster rate than the national average, and growing interest in state-of-the-art technologies could lead more venture capitalists to pursue biotechnology opportunities.
Additionally, the Post-Bulletin reports that Minnesota's Mayo Clinic Business Accelerator is helping some venture capital firms find new biotechnology investments. Versant is one such company, and devoted roughly $40 million toward Minnesota businesses recently.
"The accelerator is a great opportunity for Versant and our portfolio companies to plug into all that is happening in [the Minnesota area]," Versant spokesperson Kirk Nielson told the news source.
Versant has about $1.6 billion in available capital, and it could dedicate resources toward bolstering the Minnesota biotechnology sector. If other venture capital firms study the value of biotechnology investments, these businesses could help the sector significantly expand.
Content provided by executive search organization, MRINetwork.